Besides, combinations like ieramilimab (an anti-LAG-3 antibody) alongside spartalizumab (an anti-PD-1 antibody) have demonstrated sustained positive responses in various patient groups, including those with non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, mesothelioma, and triple-negative breast cancer (TNBC). Here, LAG3 is linked to non-small cell lung carcinoma.